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Abstract
Telomeres are critical in maintaining genomic stability. Genetic variants in telomere pathway genes may affect telomere and
telomerase function, and subsequently cancer risk. We evaluated 126 SNPs from 10 genes related to telomere regulation in
relation to bladder cancer risk. Five SNPs, 4 from TEP1 gene and 1 from PINX1 gene, were found to be highly significant
(P,0.01). Out of these, the most significant association was found in rs2228041 of TEP1 (OR 1.66, 95% CI 1.19–2.31) while
rs1469557 of PINX1 had a protective effect (OR 0.75, 95% CI 0.61–0.93). Haplotype analysis showed that a TEP1 haplotype
consisting of the variant alleles of 7 SNPs exhibited a 2.28 fold increased risk (95% CI 1.13–4.60). We then performed
cumulative analysis of multiple risk variants, as well as Classification and Regression Tree (CART) to look for gene-gene
interactions. In cumulative effect analysis, the group with 4–5 risk variants had an OR of 2.57 (95% CI=1.62–4.09) versus the
reference group with 0 risk variants. The CART analysis categorized individuals into five subgroups with different bladder
cancer risk profiles based on their distinct genotype background. To our knowledge, this is one of the largest, most
comprehensive studies on bladder cancer risk concerning telomere-regulating pathway gene SNPs and our results support
that genetic variations of telomere maintenance modulate bladder cancer risk individually and jointly.
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Introduction
Telomeres form the ends of chromosomes and consist of
nucleotide TTAGGG sequence repeats and the associated protein
complex shelterin in mammalian cells [1,2]. Telomeres prevent
the ends of chromosomes from being recognized as double-strand
breaks and are vital for genomic integrity, preventing end-to-end
fusion, nucleolytic degradation, and atypical recombination [3].
The shelterin complex, composed of six core proteins, helps to
prevent recognition of telomeres by DNA damage repair pathways
[2], and also modulates telomerase activity [2,4]. Telomerase,
a specialized reverse transcriptase, adds TTAGGG repeats to
elongate telomeres using an internal RNA template [5].
In somatic cells, telomeres progressively shorten by 30 to 200 bp
aftereach mitoticdivision duetoincompletereplication oftelomeric
DNA by DNA polymerases, known as the end-replication problem
[6]. When telomere length becomes critically short, loss of telomere
protection results in initiation of cell senescence and eventually
leads to apoptosis, triggering DNA damage response at telomeric
chromosome ends which are recognized as double-strand breaks
[7]. However, such a process results in strong selection for cells with
defective DNA damage responses that can bypass this telomere
checkpoint [8]. Unlimited proliferation is gained through upregula-
tion of telomerase that compensates for telomere erosion in cancer
cells [9]. Telomerase activity has beendetected in,85%ofcancers,
and is a characteristic of most cancers [10,11]; in several TERT-
transgenic mouse models, constitutive telomerase expression
increased cancer incidence [12]. Loss of telomere function and
continued proliferation leads to end-to-end fusions, broken
chromosomes, breakage-fusion bridge cycles, and general genetic
instability; the result is accelerated genetic changes responsible for
further growth advantages and cancer cell development [13].
The inverse relationship between telomere length and age has
also been well documented [9]. The rate of telomere attrition is
dependent on many factors: smoking, obesity, unhealthy lifestyle,
and oxidative stress are all associated with shorter telomeres [14].
Genetics strongly influence telomere length and genetic heritability
of leukocyte telomere length has been estimated at around 80%
[15]. Telomere shortening has been associated with increased risks
of several cancers, with bladder cancer being the most consistent
[16]. Previous studies have found that single-nucleotide polymor-
phisms (SNPs) in telomere pathway genes associated with altered
cancer risk; for example, a recent study found variants of
telomerase-associated protein (TEP1) associated with increased
bladder cancer risk [17]. In this current study, we took a pathway-
based approach to evaluate the association of haplotypetagging and
functional SNPs in critical telomere maintenance genes, including
shelterin component, telomerase, and telomere/telomerase associ-
ated genes, with bladder cancer risk in a large case-control study.
Results
Patient characteristics
A total of 803 Caucasian patients diagnosed with bladder cancer
and 803 Caucasian control subjects were included in this study
(Table 1). Cases and controls were matched on sex (p=0.95) and
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e30665age (p=0.10). Cases had a higher percentage of current smokers
(47.45%) versus controls (23.29%, p=5.15E-21), and among ever
smokers, cases had a higher mean pack year (43.02630.73 years)
versus controls (29.92627.87 years, p=2.78E-12).
Risk associated with individual SNPs
Among the 126 assayed SNPs, 24 SNPs (19%) were significantly
associated with bladder cancer risk at the 5% level. After removing
SNPs with high linkage (r
2.0.8 between a few tagging SNPs and
coding SNPs), 18 SNPs remained for the subsequent analysis
(Table 2). It is noteworthy that 7 SNPs in both the TEP1 and
PINX1 gene were significant at p,0.05. All of the SNPs in TEP1
were associated with increased risk, and all SNPs except one in
PINX1 were associated with reduced risk of bladder cancer.
One SNP in POT1, one in TRF2, and two in TNKS were also
significant. Since multiple testing was performed, we calculated the
Q value (a false discovery rate adjusted P value) to adjust the
significance level for individual SNPs and the Q values for these 18
SNPs were between 0.08 and 0.12 (data not shown).
Of particular interest, 5 SNPs were found to be highly
significant (p,0.01), 4 from TEP1 and 1 from PINX1. The
breakdown of these SNPs is found in Table 3. Out of these, the
most significant association was found in rs2228026 of TEP1
(OR 1.72, 95% CI 1.20–2.44), while the rs1469557 of PINX1 had
a protective effect (OR 0.75, 95% CI 0.61–0.93). To explore
interactions of genetic variants with smoking status, age, and
tumor stage, we performed stratified analysis on these 5 highly
significant SNPs, but we did not notice any significant difference of
ORs in never and ever-smokers, in old aged and young aged
individuals, and in non-muscle invasive and muscle-invasive
tumors (data not shown).
Because many SNPs of the TEP1 gene were associated with
increased risk, and 4 out of 5 highly significant SNPs were from
TEP1, we performed haplotype analysis on the 7 significant TEP1
SNPs (Table 4). Compared to the halpotype with the wild-type
alleles at all the 7 SNPs, the haplotype containing the variant
alleles at all the 7 SNPs exhibited a significantly increased risk (OR
2.28, 95% CI 1.13–4.60, p=0.022). None of the other haplotypes
showed significance in affecting bladder cancer risk.
Combined effect of multiple SNPs
The 5 highly significant SNPs (p,0.01) were considered for
cumulative effects of SNPs on bladder cancer risk. We found a
significant gene-dosage effect for increasing bladder cancer risk
with increasing number of unfavorable genotypes (p for
trend=3.31E-06), and patients were categorized into 3 risk
groups according to number of unfavorable genotypes. Compared
to individuals with no unfavorable genotypes, the risk of bladder
cancer progressively increased with addition of unfavorable
genotypes, with ORs of 1.2 (95% CI 0.92–1.62) for low-risk
group with 1 unfavorable genotype, 1.64 (95% CI 1.22–2.21) for
medium-risk group with 2–3 unfavorable genotypes, and 2.57
(95% CI 1.62–4.09) for high-risk group with 4–5 unfavorable
genotypes (Table 5).
CART Analysis
All significantly associated SNPs (Table 2) were analyzed for
potential gene-gene interactions through CART analysis. The
initial split was at rs2228041 of TEP1, the most significant SNP
out of those evaluated for bladder cancer risk. The final tree had 5
terminal nodes (Figure 1). Table 6 summarizes the risk estimates
for individuals in each terminal node. Node 1 (N=101), used for
reference, had the lowest risk and comprised of patients who were
GG for rs11250080 on PINX1, TC/CC for rs1469557 on PINX1,
and AA for rs2228041 on TEP1. Compared to individuals in node
1, the other nodes were associated with increased bladder cancer
risk with ORs ranging from 1.74 to 3.28 based on distinct
Table 1. Distribution of select characteristics among study subjects.
Category Subcategory Control subjects Case patients P value
Sex, No. (%) Male 639 (79.58) 640 (79.70)
Female 164 (20.42) 163 (20.30) 0.9506
Smoking status, No. (%) Never 355 (44.21) 212 (26.40)
Former 381 (47.45) 404 (50.31)
Current 67 (8.34) 187 (23.29) 5.15610
221
Age, Mean (SD) 63.82 (10.88) 64.73 (11.13) 0.0982
Pack year, Mean (SD) 29.92 (27.87) 43.02 (30.73) 2.78610
212
doi:10.1371/journal.pone.0030665.t001
Table 2. Individual SNPs associated with bladder cancer risk.
SNP Gene Chr Model OR (95CI) P value
rs1469557 PINX1 8 DOM 0.75 (0.61–0.93) 0.0077*
rs17152584 PINX1 8 DOM 0.76 (0.60–0.96) 0.0186
r s6995541 PINX1 8 ADD 0.82 (0.70–0.97) 0.0199
rs9657541 PINX1 8 DOM 0.78 (0.63–0.97) 0.0220
rs11250080 PINX1 8 REC 0.66 (0.46–0.95) 0.0250
rs7826180 PINX1 8 REC 0.60 (0.38–0.96) 0.0301
rs2409655 PINX1 8 DOM 1.24 (1.01–1.52) 0.0392
rs4360236 POT1 7 DOM 0.75 (0.58–0.97) 0.0261
rs2228041 TEP1 14 DOM 1.66 (1.19–2.31) 0.0023
rs2228026 TEP1 14 DOM 1.72 (1.20–2.44) 0.0025
rs1713418 TEP1 14 REC 1.42 (1.10–1.83) 0.0075
rs2297615 TEP1 14 ADD 1.24 (1.05–1.46) 0.0097
rs2229101 TEP1 14 DOM 1.46 (1.06–2.00) 0.0192
rs2104978 TEP1 14 DOM 1.40 (1.03–1.91) 0.0309
rs1713440 TEP1 14 ADD 1.17 (1.01–1.35) 0.0403
rs251796 TERF2 16 DOM 1.53 (1.08–2.16) 0.0154
rs7825818 TNKS 8 DOM 1.32 (1.06–1.64) 0.0118
rs10503380 TNKS 8 ADD 1.21 (1.03–1.43) 0.0234
*SNPs with P-values,0.01 were bolded.
doi:10.1371/journal.pone.0030665.t002
Telomere-Maintenance Genes SNPs and Bladder Cancer
PLoS ONE | www.plosone.org 2 February 2012 | Volume 7 | Issue 2 | e30665genotype combinations. Individuals in node 5 (N=177) with AG/
GG for rs2228041 on TEP1 had the highest risk (OR 3.28, 95%
CI 1.94–5.57).
Discussion
This study evaluated the association between a set of SNPs in
telomere maintenance genes and bladder cancer risk. Eighteen
significant SNPs were found: among SNPs with very significant
association (p,0.01), 4 were from telomerase protein component
1( TEP1) and 1 was from PIN2/TRF1-interacting protein 1
(PINX1). We also found a significant cumulative effect of multiple
SNPs, and potential gene-gene interactions concerning risk.
Telomere shortening and telomerase activation is linked to
genomic instability and tumorigenesis. Many studies showed that
shorter telomere length is associated with higher risk of several
cancers [18,19,20,21,22,23,24], with the strongest evidence in
bladder cancer [25]. Telomerase is active in most cancers and is
critical for tumorigenesis. It is likely that the studied genetic variants
affect cancer risk through changes in mechanisms involving
telomere regulation, telomere length, or telomerase function.
Previous studies have shown selected genetic variants in genes of
telomere pathway and bladder cancer risk [26,27]. TEP1 is a
component of the ribonucleoprotein complex and binds to
telomerase.A SNP (rs1760897)inTEP1hasrecentlybeenassociated
with an increased riskofbladdercancer [17]. Wealso genotyped this
SNP in this current study and found this SNP was associated with a
borderline significantly increased risk of bladder cancer (OR 1.17,
95% CI 0.94–1.45 and OR 1.27, 95% CI 0.91–1.79 for
heterozygous and homozygous variant genotypes, respectively; p
Table 3. Logistic regression analysis of highly significant SNPs (P,0.01).
SNP Gene Genotype Cases (%) Controls (%) OR (95CI) P value Q value
zrs2228041 TEP1 GG 734 (91.41) 694 (86.64) 1 (ref)
GA 67 (8.34) 107 (13.36) 1.69 (1.21–2.36)
AA 2 (0.25) 1 (0.12) 0.52 (0.04–7.38)
AA+GA vs. GG 1.66 (1.19–2.31) 0.0023 0.089
rs2228026 TEP1 TT 744 (92.65) 709 (88.51) 1 (ref)
TC 57 (7.10) 93 (11.61) 1.75 (1.23–2.50)
CC 2 (0.25) 1 (0.12) 0.52 (0.36–7.38)
CC+TC vs. TT 1.72 (1.20–2.44) 0.0025 0.089
rs1713418 TEP1 TT 268 (33.37) 244 (30.46) 1 (ref)
TC 397 (49.44) 379 (47.32) 1.02 (0.81–1.29)
CC 138 (17.19) 180 (22.47) 1.43 (1.07–1.92)
CC+TC vs. TT 1.42 (1.10–1.83) 0.0075 0.110
rs2297615 TEP1 TT 475 (59.15) 428 (53.43) 1 (ref)
TA 284 (35.37) 314 (39.20) 1.21 (0.98–1.50)
AA 44 (5.48) 61 (7.62) 1.61 (1.06–2.46)
Additive 1.24 (1.05–1.46) 0.0097 0.110
rs1469557 PINX1 CC 485 (60.40) 532 (66.42) 1 (ref)
CT 283 (35.24) 244 (30.46) 0.76 (0.61–0.94)
TT 35 (4.36) 27 (3.37) 0.70 (0.41–1.20)
TT+CT vs. CC 0.75 (0.61–0.93) 0.0077 0.110
doi:10.1371/journal.pone.0030665.t003
Table 4. Haplotype analysis of TEP1 gene.
Haplotype group* Controls (%) Cases (%) OR (95CI) P value
W-W-W-W-W-W-W 551 (46.85) 482 (43.11) 1 (ref)
W-W-W-W-W-W-M 187 (15.90) 178 (15.92) 1.12 (0.87–1.43) 0.3836
M-W-W-W-W-W-W 136 (11.56) 128 (11.45) 1.06 (0.80–1.40) 0.6750
M-W-W-M-W-W-W 131 (11.14) 123 (11.00) 1.08 (0.80–1.44) 0.5921
M-W-W-W-W-W-M 54 (4.59) 61 (5.46) 1.32 (0.88–1.96) 0.1751
M-W-W-M-W-W-M 49 (4.17) 60 (5.37) 1.42 (0.95–2.14) 0.0896
M-M-M-M-M-M-M 13 (1.11) 25 (2.24) 2.23 (1.13–4.60) 0.0220**
M-M-M-M-M-M-W 14 (1.19) 17 (1.52) 1.34 (0.63–2.84) 0.4467
M-M-W-M-W-W-M 12 (1.02) 16 (1.43) 1.81 (0.84–3.91) 0.1304
Other 29 (2.47) 28 (2.50) 1.07 (0.62–1.84) 0.8083
*Order of SNPs: rs1713418, rs2104978, rs17211355, rs2297615, rs2228041,
rs2228026, rs1713440.
**Haplotype with a P-value,0.05 was bolded.
doi:10.1371/journal.pone.0030665.t004
Table 5. Cumulative analysis of the top 5 most significant
SNPs.
Genotypes Controls (%) Cases (%) OR (95CI) P value
0 171 (21.30) 129 (16.08) 1 (ref)
1 364 (45.33) 327 (40.77) 1.2 (0.92–1.62) 0.1670
2,3 228 (28.39) 272 (33.92) 1.64 (1.22–2.21) 0.0011
4,5 40 (4.98) 74 (9.22) 2.57 (1.62–4.09) 6.46610
25
p for trend 3.31610
26
doi:10.1371/journal.pone.0030665.t005
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associated with increased bladder cancer risk. The most signifi-
cant SNP was rs2228041. This SNP is a non-synonymous SNP,
Arg1155Gln. Changing a strong basic amino acid (arginine) to a
neutral amino acid(glutamine)islikelyto affectprotein structureand
function. Future studies are needed to determine how this TEP1
SNP affects TEP1 function, telomerase activity, and bladder cancer
risk. Our haplotype analysis also supports the role of TEP1 in
bladder cancer etiology.
In addition to TEP1, we found high significance in a SNP on the
PINX1 gene and lower bladder cancer risk. PINX1 regulates
telomerase function and can directly bind to TERT and inhibit
telomerase activity; inhibition of PINX1 increases telomerase
activity, while overexpression does the opposite [28]. A previous
study showed that PINX1 inhibition leads to aberrant telomerase
activation and telomere elongation, compromising telomere
function and causing chromosomal instability, and there is
evidence supporting the role of PINX1 as a tumor suppressor,
acting through a telomerase-dependent mechanism [29]. Our
findings provide further support that PINX1 is a potential tumor
suppressor. Potentially, genetic variation of the PINX1 gene could
alter cancer risk through mechanisms of telomere regulation, and
more studies are warranted to evaluate genetic variants within the
PINX1 gene and association with bladder cancer risk, as well as to
define how PINX1 regulates telomeres through telomerase-
dependent or independent mechanisms.
We performed cumulative analysis of multiple SNPs. Although
the analyzed SNPS individually had moderate effect on bladder
cancer risk, we found a stronger cumulative effect. These results
confirm the multigenicity of bladder cancer, as noted in previous
studies [30,31,32], and identification of multiple risk variants could
further improve risk prediction. As well, we performed CART
analysis to explore high order gene-gene interactions among SNPs.
Since bladder cancer is a multi-factor disease, interactions between
genetic variations as well as environmental factors such as smoking
and occupational exposure, are likely to contribute with an
accumulative effect to risk.
There are several strengths of this study. The sample size is
relatively large for a candidate gene study. The study population is
homogeneous with minimal confounding of population structure.
The patients were all histologically confirmed. The SNP panel is
comprehensive. There are also a few limitations of this study. We
used a false discovery rate (FDR) based approach to adjust for
multiple testing and the FDR-adjusted P values were between 0.08
and 0.12 for the significant SNPs. A FDR threshold of 0.2 was
suggested by previous studies for candidate gene studies [33].
Figure 1. The tree structure of the CART analysis of interaction effects between the 18 top variants (P,0.05, Table 2) in modulating
bladder cancer risk.
doi:10.1371/journal.pone.0030665.g001
Table 6. Logistic regression analysis of terminal nodes in
CART analysis.
CART node Controls (%) Cases (%) OR (95CI) P value
1 67 (8.34) 34 (4.24) 1 (ref)
2 104 (12.95) 83 (10.36) 1.74 (1.04–2.93) 0.0363
3 228 (28.39) 199 (24.84) 1.82 (1.14–2.90) 0.0123
4 335 (41.72) 377 (47.07) 2.35 (1.49–3.69) 2.17610
24
5 69 (8.59) 108 (13.48) 3.28 (1.94–5.57) 1.02610
25
p for trend 1.28610
26
doi:10.1371/journal.pone.0030665.t006
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validations in independent studies are warranted to confirm the
results of our studies. In addition, the CART analysis was
exploratory and the results should be interpreted with caution.
Nevertheless, our study strongly suggests that genetic variations in
telomere maintenance genes modulate bladder cancer risk
individually and jointly.
Materials and Methods
Ethics Statement
All patients signed a written informed consent and this study has
been reviewed and approved by the Institutional Review Boards
(IRB) of MD Anderson Cancer Center, Baylor College of
Medicine, and Kelsey-Seybold Clinic.
Study population and data collection
This study included bladder cancer patients who were recruited
from The University of Texas MD Anderson Cancer Center and
BaylorCollegeofMedicine,recruitmentstartingin1999.Caseswere
all histopathologically confirmed and previously untreated for
chemotheraphy or radiotherapy pre-recruitment. There were no
restrictions of recruitment on age, gender, or stage. Control subjects
were recruited from Kelsey Seybold, the largest private multispe-
cialty physician group in Houston. They were healthy individuals
with no prior history of cancer except non-melanoma skin cancer,
and were matched to patient cases by age (65 years), sex, and
ethnicity. Detailed questionnaire data including demographics,
family history, smoking status, alcohol drinking, occupational
history, and medical history were collected from all subjects through
personal interview. Individuals who had smoked less than 100
cigarettesintheirlifetimesweredefinedasneversmokers,individuals
who had smoked at least 100 cigarettes in their lifetime but had quit
morethan 12 monthsprior to diagnosis(cases)or interview (controls)
were defined as former smokers, and individuals who were currently
smoking or who had stopped ,1 year prior were defined as current
smokers. Former and current smokers were defined as ever smokers.
Response rates for cases and controls were 92% and 76.7%,
respectively. Because 90.6% of the patient population was
Caucasian, we included only Caucasians in this study.
SNP selection and genotyping
We selected 10 of the most important genes coding for proteins
involved in telomere maintenance, including telomerase, shelterin
proteins, and several telomere associated proteins, based on
literature mining. Tagging SNPs were selected by the binning
algorithm of LDSelect software (http://droog.gs.washington.edu/
ldSelect.pl) (r
2,0.8, MAF.0.05) within 10 kb upstream of the 59
untranslatedregion(UTR)and 10 kb downstreamof the 39 UTR of
each gene. We also included all the confirmed coding SNPs in the
dbSNP database (http://www.ncbi.nlm.nih.gov/projects/SNP/).
The final number of SNPs for each gene region was as follows:
PINX1, 27; POT1, 8; PIP1, 1; TEP1, 42; TRF2, 2; TRF2IP, 2;
TERT, 12; TNKS, 21; TNKS1BP1, 5; and TNKS2, 6. Genomic
DNA was isolated from peripheral blood using the QIAamp DNA
Blood Maxi Kit (Qiagen) according to the manufacturer’s protocol.
Genotyping was done using Illumina’s iSelect custom SNP array
platform according to the manufacturer’s Infinium II assay protocol
(Illumina). Genotyping data was then analyzed and exported using
BeadStudio software (Illumina). The average call rate for the SNP
array was .99%. Randomly selected 2% of samples were run in
duplicates and the concordance of genotype calls was .99.9% for
duplicated samples.
Statistical analysis
Statistical analysis was performed using STATA 10.0 software
(Stata Corp). x
2 test and Fisher’s exact test were used to compare
categorical variables, and Student’s t test was used for continuous
variables. Goodness-of-fit x
2 analysis was used to test Hardy-
Weinberg equilibrium. Effects of SNP on bladder cancer risk was
estimated as odds ratio (OR) and 95% confidence interval (CI).
Unconditional multivariable logistic regression was performed
under dominant, recessive, and additive models of inheritance
adjusting for age, gender, and smoking status, where appropriate.
False discovery rate (FDR) based Q value was calculated for
individual SNP to adjust for multiple testing. We used a threshold
of 0.20 for the Q value, previously suggested as more appropriate
for moderate-sized studies with candidate gene approaches [33].
Haplotype analysis was conducted on SNPs of the TEP1 gene.
For the cumulative effect of multiple SNPs on cancer risk, SNPs
with significant association (P value for best fitting model ,0.01)
were evaluated. Using the subject group without any unfavorable
genotypes as the reference, ORs and 95% CIs were calculated for
the other groups using unconditional multivariate logistic
regression adjusted for age, gender, smoking status and pack
years. Unfavorable genotypes were sub-categorized into 3 groups
(low-, medium-, and high-risk) according to number of unfavor-
able genotypes. The reference group was one without any
unfavorable genotypes. High-order gene-gene interactions were
explored via Classification and Regression Tree (CART) analysis,
performed using HelixTree Genetics Analysis Software (v. 4.1.0,
Golden Helix). Briefly, CART uses recursive partitioning to create
a decision tree enabling identification of different combinations of
variables at varying levels of risk. Analysis starts with the root node
with all cases and controls, determines the most optimal split, i.e.
smallest P value, for each following node, with multiplicity-
adjusted P values to control tree growth (p,0.05). The process
continues until terminal nodes have no statistically significant split
or reach a predetermined minimum size. ORs and 95% CIs for
each terminal node were calculated using logistic regression. P
value#0.05 was considered to be the threshold for significance in
this study; all statistical analyses were two-sided.
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